Technology
Health
Biotechnology
Summit Therapeutics
$1.719876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$1.71
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.10 (6.21%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell SMMT and other stocks, options, ETFs, and crypto commission-free!
About
Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company operates through the Drug Development segment, which covers its research and development activities carried out by the Group. Read More Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.
Employees
61
Headquarters
Abingdon, Oxfordshire
Founded
2004
Market Cap
51.65M
Price-Earnings Ratio
2.86
Dividend Yield
—
Average Volume
88.25K
High Today
$1.72
Low Today
$1.67
Open Price
$1.69
Volume
5.96K
52 Week High
$14.12
52 Week Low
$1.10
Collections
Technology
Health
Biotechnology
Therapy
Research And Development
2015 IPO
UK
Europe
News
Yahoo FinanceMay 7
Does Summit Therapeutics plc's (LON:SUMM) CEO Pay Matter?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Glyn Edwards has been the CEO of Summit Therapeutics plc (LON:SUMM) since 2012. First, this article will compare CEO compensation with compensation at similar sized companies. Then we'll look at a snap shot of the business growth. And finally we will reflect on how common stockholders have fared in the last few years, as a secondary measure of performance. This process should give us ...
Price Paid on Robinhood
22% Lower
Right Now
52 Week Low
$1.10
Average Price Paid
$2.18
52 Week High
$14.12
Earnings
-$0.53
-$0.21
$0.10
$0.42
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected Jun 4, Pre-Market